



Amylin Pharmaceuticals, Inc.
9360 Towne Centre Drive
San Diego, CA 92121 USA

Tel (858) 552 2200
Fax (858) 552 2212
www.amylin.com

Amylin is committed to maximizing the value of exenatide for patients and physicians across the globe

Amylin is excited to assume full responsibility for developing and commercializing exenatide, the active ingredient in BYETTA® (exenatide) injection and BYDUREON™ (exenatide extended-release for injectable suspension). As Amylin enters this new era, our commitment to delivering maximum value to patients and physicians has never been stronger.

Our intent is to provide uninterrupted patient supply in all markets, including Japan where BYETTA was recently launched and the United Kingdom and Germany where BYDUREON was recently launched. We anticipate working with one or more partners outside the U.S. to ensure continuity of patient care. Amylin would like to underscore our commitment to the long-term support of exenatide in all of the countries in which exenatide is currently available, as well as additional markets in the future.

Amylin is dedicated to the exenatide franchise and will continue to develop the GLP-1 market. Our goal is to change the way diabetes is treated globally, and we have the tools, motivation, and mindset to make this happen.